In a bull market, when fancied sectors command premium valuations, IPOs in that space also come with a stiff asking price. We have seen this in the chemicals space. However, when a sector has been languishing for long and sees pick up only in pockets, will an IPO from such a sector leave money on the table? More specifically, will GR Infraprojects be one such offer? Read our take.
IPO Review: GR Infraprojects Read More »
India Pesticides is launching an IPO totalling to Rs 800 crore – with fresh issue of shares worth Rs 100 crore and an offer for sale worth Rs 700 crore by the promoter group. At the upper end of the price band of Rs 290-296 the post-issue market cap of the stock on listing would be Rs3,400 crore and the post-issue price earnings ratio would be 25 times. The offer closes on June 25. The proceeds from fresh issues are planned to be utilised towards working capital requirement and other corporate purposes.
IPO Review: India Pesticides Limited Read More »
KIMS Hospitals or Krishna Institute of Medical Sciences Hospital is a multi-speciality hospital chain with 9 centres, focused on the Andhra Pradesh-Telangana region. The KIMS Hospital IPO seeks to raise a sizeable Rs 2,143 crore (at the upper end of its price band of Rs 815-825). Of this, Rs 1943 crore is an offer for sale from PE investor General Atlantic, the promoters, and 44 other shareholders. The remaining will be used to pay off the already low borrowings and for general corporate purposes. Does the KIMS Hospital IPO make for a good long-term bet?
IPO review – KIMS Hospitals Read More »
Automotive components manufacturer Sona BLW Precision Forgings (Sona Comstar) has come out with an IPO totalling to Rs 5,550 crore – with fresh issue of shares at Rs 300 crore and Rs 5,250 crore of an offer for sale by private equity investors and promoters. At the upper end of the price band of Rs
IPO Review: Sona BLW Precision Forgings Read More »
New share offers are a thing of joy in a bull market. They promise to bring quick gains within two days of investing the money. In season, too many people chase the IPO, the allotment is a lottery and most retail folks get allotment of shares valued at about Rs.15,000, which is considered as “one lot”. And of course, there is the “HNI” category where you have a shot at bigger allotments. Many resort to NBFC funding which is available in plenty, to improve their odds in this lottery.
Reading an IPO prospectus: what it says and what it doesn’t Read More »
Small finance banks, with their focus on small ticket loans for urban and semi-urban India, are a play on the underpenetrated market for financial products in India. Yet, after stellar performances soon after their IPOs many of these stocks have seen their valuations levelled. So, when a new candidate – Suryoday Small Finance Bank IPO (Suryoday) comes out in an overcrowded primary market, how should it be judged? Read on.
Suryoday Small Finance Bank IPO – Invest or avoid? Read More »
Kalyan Jewellers’ IPO is upon us and Aarati is here with the most detailed analysis and opinion piece on the offering – Should you buy or not? Either way, read this article first!
Kalyan Jewellers’ IPO – Should you invest? Read More »
The Mrs Bectors IPO, open now and closing on December 17th, has a price band of Rs 286-288, and seeks to raise up to Rs 540.54 crore. With broad-based revenues and strong regional brands, should you go for this IPO?
Mrs. Bectors Food Specialties IPO – Should you invest? Read More »
Burger King, ‘Home of the Whopper’, needs little introduction. , Burger King India holds the exclusive pan-India right to open and operate outlets under the global Burger King brand. The company is part of the growing quick service restaurant (QSR) industry in India. And despite being a relatively new entrant to this space – the
Burger King India IPO – Should you subscribe? Read More »
The Initial Public Offer (IPO) of UTI AMC is hitting the markets today and will close on October 1. This offer of 3.89 crore shares to the public is made up entirely of sale of shares by UTI’s key shareholders – SBI, LIC and Bank of Baroda. In addition, T Rowe Price International Ltd, a long-standing global investor in UTI and PNB a sponsor, are also selling a small part of their holdings. UTI AMC will not receive any capital infusion from these divestments.
Should you subscribe to the UTI AMC IPO? Read More »
Legal Disclaimer : PrimeInvestor Financial Research Pvt Ltd (with brand name PrimeInvestor) is an independent research entity offering research services on personal finance products to customers. We are a SEBI registered Research Analyst (Registration: INH200008653). The content and reports generated by the entity does not constitute or is not intended to constitute an offer to buy or sell, or a solicitation to an offer to buy or sell financial products, units or securities. All content and information are provided on an ‘as is’ basis by PrimeInvestor Financial Research Pvt Ltd. Information herein is believed to be reliable but PrimeInvestor Financial Research Pvt Ltd does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. The services rendered by PrimeInvestor Financial Research Pvt Ltd are on a best-effort basis. PrimeInvestor Financial Research Pvt Ltd does not assure or guarantee the user any minimum or fixed returns. PrimeInvestor Financial Research Pvt Ltd or any of its officers, directors, partners, employees, agents, subsidiaries, affiliates or business associates will not liable for any losses, cost of damage incurred consequent upon relying on investment information, research opinions or advice or any other material/information whatsoever on the web site, reports, mails or notifications issued by PrimeInvestor Financial Research Pvt Ltd or any other agency appointed/authorised by PrimeInvestor Financial Research Pvt Ltd. Use of the above-said information is at the user’s own risk. The user must make his own investment decisions based on his specific investment objective and financial position and using such independent advisors as he believes necessary. All intellectual property rights emerging from this website, blog, and investment solutions are and shall remain with PrimeInvestor Financial Research Pvt Ltd. All material made available is meant for the user’s personal use and such user shall not resell, copy, or redistribute the newsletter or any part of it, or use it for any commercial purpose. PrimeInvestor Financial Research Pvt Ltd, or any of its officers, directors, employees, or subsidiaries have not received any compensation/ benefits whether monetary or in kind, from the AMC, company, government, bank or any other product manufacturer or third party, whose products are the subject of its research or investment information. The performance data quoted represents past performance and does not guarantee future results. Investing in financial products involves risk. Investments are subject to market risk. Please read all related documents carefully. As a condition to accessing the content and website of PrimeInvestor Financial Research Pvt Ltd, you agree to our Terms and Conditions of Use, available here. This service is not directed for access or use by anyone in a country, especially the USA, Canada or the European Union countries, where such use or access is unlawful or which may subject PrimeInvestor Financial Research Pvt Ltd or its affiliates to any registration or licensing requirement.
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Compliance Officer Details: Name: Srikanth Meenakshi; Email: contact@primeinvestor.
Grievance Officer Details: Name: Srikanth Meenakshi; Email: contact@primeinvestor.
